Sfoglia per AUTORE
LAROCCA A
Collezione AO Cuneo

  

Items : 6

Immune dysfunctions affecting bone marrow V?9V?2 T cells in multiple myeloma: Role of immune checkpoints and disease status. in Frontiers in immunology / Front Immunol. 2022 Dec 20;13:1073227. doi: 10.3389/fimmu.2022.1073227. eCollection 2022.

2022
AOU Città della Salute di Torino
AO Cuneo

Avonto I; Massaia M; Riganti C; Grasso M; Kopecka J; D'Agostino M; Larocca A; Tripoli E; Grimaldi D; Castella B; Giannotta C;

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Bonello F; Monaco F; Corradini P; Boccadoro M; Offidani M; Mina R; Ballanti S; De Sabbata G; Aquino S; De Paoli L; Grasso M; Cellini C; Paris L; Belotti A; Tacchetti P; Cea M; Zambello R; Musolino C; Patriarca F; Rota-Scalabrini D; Capra A; Pescosta N; Petrucci MT; Ciccone G; Bringhen S; Liberati AM; Falcone AP; Larocca A;

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Biella
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Alessandria

Sonneveld P; Boccadoro M; Larocca A; Musto P; Romano A; Ria R; Giuliani N; Offidani M; Liberati AM; Marchetti M; Mosca-Siez ML; de Fabritiis P; Ballanti S; Monaco F; Gobbi M; Cellini C; Grasso M; Ronconi S; Pescosta N; Petrucci MT; Capra A; Zambello R; Mina R; Di Lullo G; Belotti A;

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.

2020
ASL Torino 4
AOU Città della Salute di Torino
AO Cuneo

Boccadoro M; Larocca A; Hájek R; Falco P; Palumbo A; Cellini C; Marasca R; Gentile M; Baldini L; Tosi P; Petrucci MT; Santoro A; Poggiu M; Aquino S; Gazzera G; De Rosa L; Pavone V; Pescosta N; Pezzatti S; Grasso M; Rota-Scalabrini D; Spada S; Paris L; Ballanti S; Bringhen S; D'Agostino M;

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Ria R; Vacca A; Dammacco F; Boccadoro M; Petrucci MT; Musto P; Montefusco V; Rizzo M; Gottardi D; Falcone AP; Grasso M; Leonardi G; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Patriarca F; Martino E; Larocca A; Offidani M; De Paoli L; Bringhen S; Palumbo A; Omedè P; Terragna C; Giuliani N; Morabito F; Saltarella I; et alii...

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...